| Bioactivity | Denileukin diftitox (DAB 389IL-2) is a diphtheria toxin (DT)-related interleukin 2 (IL-2) fusion protein toxin that depletes cells expressing the high-affinity form of the IL-2 receptor (IL-2R), CD25. Denileukin diftitox binds to cells expressing IL-2R and inhibits protein synthesis through internalization of the diphtheria toxin fragment[1][2][3]. |
| Target | IL-2 receptor (IL-2R), CD25 |
| Invitro | Denileukin diftitox (DAB 389IL-2) 是一种 3 结构域融合蛋白毒素，由白喉毒素 (DT) 催化结构域、白喉毒素 (DT) 膜易位结构域和取代天然白喉毒素 (DT) 受体结合结构域的人 IL-2 组成[1]。Denileukin diftitox (1-1000 pM; HUT 102/6TG 细胞) 对于体外携带高亲和力 IL-2 受体的细胞系细胞毒效力增加了大约 17 倍[3]。 |
| In Vivo | Denileukin diftitox (DAB 389IL-2; 35 μg/kg; i.p.; 感染 H37Rv 的 C57BL/6 小鼠) 在小鼠模型中抑制分枝杆菌复制并降低 Treg 和髓源性抑制细胞 (MDSC) 的频率[1]。Denileukin diftitox (2.5 或 3 μg/头; i.v.) 在小鼠模型中具有抗肿瘤活性并抑制肿瘤生长[2]。 Animal Model: |
| Name | Denileukin diftitox |
| CAS | 173146-27-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gupta S, et, al. Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis. J Infect Dis. 2017 Jun 15;215(12):1883-1887. [2]. Albu DI, et, al. Preclinical immune antitumor activity of myeloid-targeting E7046 and Treg depleting E7777. Cancer Immunol Res (2016) 4 (1_Supplement): B034. [3]. Kiyokawa T, et, al. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng. 1991 Apr;4(4):463-8. |